Altimmune, Inc. (NASDAQ:ALT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have been assigned a consensus rating of “Moderate Buy” from the six research firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $18.80.

A number of analysts have recently commented on ALT shares. Guggenheim cut Altimmune from a “buy” rating to a “neutral” rating in a research note on Monday, April 29th. B. Riley reissued a “buy” rating and set a $20.00 target price on shares of Altimmune in a research note on Tuesday. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price target on shares of Altimmune in a research report on Friday, June 21st. JMP Securities reduced their price target on Altimmune from $25.00 to $24.00 and set a “market outperform” rating for the company in a research report on Friday, May 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Tuesday, May 14th.

Institutional Investors Weigh In On Altimmune

Several large investors have recently made changes to their positions in the stock. Cetera Advisors LLC boosted its holdings in shares of Altimmune by 19.6% in the 1st quarter. Cetera Advisors LLC now owns 60,800 shares of the company’s stock valued at $619,000 after buying an additional 9,977 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in Altimmune by 1,282.4% during the 1st quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock valued at $4,785,000 after purchasing an additional 436,000 shares during the last quarter. Tidal Investments LLC acquired a new stake in Altimmune during the 1st quarter valued at $141,000. California State Teachers Retirement System lifted its holdings in Altimmune by 517.7% during the 1st quarter. California State Teachers Retirement System now owns 53,730 shares of the company’s stock valued at $547,000 after purchasing an additional 45,032 shares during the last quarter. Finally, Knoll Capital Management LLC lifted its holdings in Altimmune by 183.6% during the 1st quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock valued at $5,774,000 after purchasing an additional 367,219 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Trading Up 3.8 %

Altimmune stock opened at $7.41 on Friday. Altimmune has a 1 year low of $2.09 and a 1 year high of $14.84. The company has a market cap of $525.37 million, a PE ratio of -4.66 and a beta of 0.11. The company’s 50-day moving average is $7.11 and its two-hundred day moving average is $8.80.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, May 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. The company had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 22,645.37% and a negative return on equity of 46.96%. During the same quarter in the previous year, the company posted ($0.40) earnings per share. Research analysts forecast that Altimmune will post -1.34 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.